Convergence Pharmaceuticals, Biogen Idec deal

Biogen is acquiring Convergence for $200 million up front and up to $475 million in milestone payments. Convergence’s CNV1014802, a state-dependent inhibitor of sodium channel subunit Nav1.7 (SCN9A)...